Editorial Policies

Aims and Scope

Russian journal of allergy is a quarterly peer-review medical journal.

The aim of the journal is to promote scientific achievements in allergology and clinical immunology, to publish original articles, reviews, lectures, information for HCP, interesting clinical case reports as well as reports about congresses, conferences and meetings. Any reader may find new scientific and practical information in the field of allergology and clinical immunology, share his/her experience, get needed knowledge on clinical practice. 

The Journal is aimed to most topical issues of allergollogy and clinical immunology: pathogenesis, diagnostics, clinical features, modern methods of treatment of the allergic and immune-mediated diseases, such as bronchical asthma, allergiс rhinitis, atopic dermatitis, urticaria, angioedema, drug allergy, primary immunodeficiency syndromes etc.

RJA is intended for practicing allergologists, immunologists, research scientists, students and teachers of the departments of allergology and immunology at higher education institutes and faculties of postgraduate education, for other professionals working in related fields and showing interest in this field of medicine.

 

Sections

Original studies

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Reviews

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Case reports

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Clinical practice guidelines

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Letters to the editor

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Short communications

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

Content selection and publication schedule

The editorial team of the Russian Journal of Allergy consider and publish articles in the order in which they are submitted. Consideration of articles includes several stages, one of which is peer-review.

The editorial board can decide to accelerate publication rate (to publish out of schedule) in cases when the submitted manuscript contains data should be brought to readers immediately and this manuscript was highly appreciated by the reviewers.

The editorial board has the right to reject the article regardless of the peer-review results.

Final editorial decisions (to accept or to reject a manuscript) are made only by the editorial board and the editor-in-chief. Positive opinions of the reviewers do not oblige the editorial board to accept the article for publication. In all conflict or unclear cases, the final editorial decision is made personally by the editor-in-chief. 

Peer-review

All research and review articles, case reports and short commucations submitted to the journal are peer reviewed/

double-blind peer review method is mandatory for processing of all research and review manuscripts, case reports and short commucations submitted to the editorial team of Russian Journal of Allergy. This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer.

  1. All the manuscripts are reviewed by the Executive editor on compliance with the journal's aims and scope, author guidelines and publication ethics statement of the journal. If inconsistencies are identified, the manuscript will be sent to the authors for revision (authors have no more than 3 months for revision). A manuscript may be rejected prior to peer-review if:
    • authors were unable to prepare manuscript in accordance with the journal's authors guidelines during three consecutive rounds of revision$
    • authors did not submit the required set of accompanying documents;
    • significant violations of the publication ethics principles were found in the manuscript by the executive editor (plagiarisms, copyright infringement, data falsification, violation of the research participants rights, etc.);
    • the authors did not complete the revision of the manuscript within the 3 months.
  2. The Executive editor prepares manuscripts (exclude all authors-specific data) for peer-review. Files and manuscript data that can identify authors will not be available for peer-reviewers.
  3. To peer-review manuscripts, we invite both members of the editorial board and independent high qualified scientists and specialists with deep professional knowledge and experience in a specific research area. We also use Publons (Clarivate) database for searching appropriate reviewers. Reviewers provide articles evaluation as independent specialists on a voluntary basis, without entering into an employment relationship with the publisher or founder of the journal.
  4. Only several persons are able to choose and invite reviwers: editor-in-chief, deputy editor-in-chief, science editor, executive editor. Each reviewer has the right to refuse the invitation at any time and for any reason, including an explicit or potential conflict of interest that could affect the perception and interpretation of the manuscript.
  5. One round of peer-review spends 2-4 weeks, but it can be extended at the request of the reviewer. Reviewer should give one of the following recommendations with appropriate justification:
    • to accept the article for publication;
    • to revise the manuscript and send it for second round of peer-review;
    • to involve additional specialists for peer-review the manuscript;
    • to reject the manuscript.
      We sent copies of reviews to authors.
  6. If the review contains recommendations for correcting and revising the manuscript, the Executive editor sends the review to authors with appropriate recommendations for preparing a new version of the manuscript. We ask authors to accompany revised manuscript by letter to reviewers with point-by-point answers on all questions and explanations of all changes made in the manuscript. The revision of the manuscript should not take more than 2 months. We send revised manuscripts for peer-review to the same reviewers. The peer-review process continues until the receive final conclusions from all the reviewers. To make a final editorial decision the Executive editor provides all the peer-reviewed manuscripts and reviewers' recommendations to the Editorial Board for consideration.
  7. If the authors are unable to revise the manuscript, they should notify the editorial team. Editorial board should reject the manuscripts if the authors will not return the revised version within 3 months after the previous editorial decision. In such situations, an appropriate notification will be sent to authors.
  8. If the authors and reviewers have insoluble contradictions regarding the manuscript, the editorial board has the right to send the manuscript for additional peer-review. In all controversial situations, only the editor-in-chief will decide to accept or to reject the manuscript .
  9. The Executive editor informs the authors via email about a final editorial decision on the article and it's expected publication date.
  10. We are continuously saving the archive with all the manuscripts and the peer-review history.

 

Publication Frequency

The journal issues quarterly, 4 times per year. Also we publish supplements and special issues.

 

Author Self-Archiving

The journal is compliant with Green Open Access mode (formerly known as Open Self-Archiving) for articles distribution.

Terms and definitions

We use the following terms and definitions:

  • Preprint: An early version of an article prior to the version submitted for publication in a journal. Theses and dissertations are considered to be preprints.
  • SMUR (Submitted Manuscript Under Review): The version of the article that is under formal review for inclusion in the journal.
  • AM (Accepted Manuscript): The version of the article that has been accepted for publication. This version may include revisions resulting from peer review but may be subject to further modification by Pharmarus Print Media (for example, copyediting and typesetting).
  • VoR (Version of Record): The version that is formally published. This not includes any Online First article that is formally identified as being published online before the compilation of a journal issue. The VoR includes any post-publication corrections.
  • Personal webpage: Web pages created by you, about you and your research which are hosted on a non-commercial website (such as your institute’s website). Personal profile pages in commercial sharing sites (such as ResearchGate, Academia.edu and Facebook) are not considered to be personal web pages.
  • Department or institutional repository: Web pages hosted by an academic or research institute or department to provide access to the work to promote and the activities of the institute or department, at all times operating for a non-commercial purpose.
  • Subject repository: Web pages hosted by an organization to provide access to the work from researchers working in a subject or range of subjects, at all times operating for a non-commercial purpose.
  • Commercial and non-commercialCommercial means any activity for direct or indirect financial gain. When considering whether a use is commercial or non-commercial, we look at the nature of the activity rather than the nature of the site or organization performing the activity.


What can be self-archived, where and when

 

 

Personal
web page

Department or institutional repository

Non-commercial subject repository
(e.g. PubMed Central)

Commercial repository or social media site
(e.g. ResearchGate, Academia.edu, SSRN)

Preprint,
SMUR

At any time

At any time

At any time

At any time

AM

On acceptance

On acceptance

On acceptance

Abstract only plus link to VoR on https://rusalljournal.ru/

VoR

Abstract only plus link to VoR on https://rusalljournal.ru/

Abstract only plus link to VoR on https://rusalljournal.ru/

Abstract only plus link to VoR on https://rusalljournal.ru/

Abstract only plus link to VoR on https://rusalljournal.ru/

 

Plan S compliance

Our Green OA policy is not compatible with Plan S, and our License to Publish agreements with authors may conflict with authors' agreements with their cOAlition S funders. Authors should publish as Gold OA in order to be compliant with Plan S.

Creative Commons and other end-user licenses

Preprints and SMURs can be made publicly accessible under any license terms the authors choose. We recommend a Creative Commons CC-BY or a more restrictive CC license.

Accepted Manuscripts can be made accessible under a Creative Commons CC-BY-NC-ND license or equivalent, but not a more permissive license. We do not allow AMs to be made accessible under a CC-BY license, for example.

Third-party material

Before posting articles online, authors should ensure they have the appropriate permission to include any third party content. When posting articles under a Creative Commons license, the permission should allow the third-party material to be included either (i) under the Creative Commons license or (ii) clearly indicated as being protected by third party copyright, with a clear notice that it cannot be reused without further permissions clearance from the identified third-party rights holder.

Closed deposits and embargo periods

Articles can be deposited in repositories before publication provided the content is only accessible to repository administration staff. This is sometimes referred to as ‘closed deposit’.

Metadata about the article (for example the article title, abstract, and journal citation) can be made public as soon as the article is published. The full text must not be made public before the embargo ends.

Any applicable embargo period starts from the date the Version of Record is first published online as part of a journal’s issue.

Posting content in repositories

We require repositories to include:

  • If an article has not yet been published, a clear statement that the material has been accepted for publication in a revised form, with a link to the journal’s site on https://rusalljournal.ru/.
  • For all published articles, a link to the article’s Version of Record in https://rusalljournal.ru/ – for example, via a DOI-based link.
  • A clear statement about the license terms under which the posted version of the article is deposited.

Example statements are:

  • This article has been published in a revised form in Russian Journal of Allergy [http://doi.org/XXX]. This version is free to view and download for private research and study only. Not for re-distribution or re-use. © copyright holder.
  • This article has been published in a revised form in Russian Journal of Allergy [http://doi.org/XXX]. This version is published under a Creative Commons CC-BY-NC-ND. No commercial re-distribution or re-use allowed. Derivative works cannot be distributed. © copyright holder.


Citing content in repositories

When citing an Accepted Manuscript or an earlier version of an article, we request that readers also cite the Version of Record with a DOI link, for example: Subsequently published in revised form in Russian Journal of Allergy [http://doi.org/XXX].

 

Delayed Open Access

The contents of this journal will be available in an open access format 24 month(s) after an issue is published.

You can get access to all Open Access content online https://rusalljournal.ru/

 

Issue Purchase

Readers without a subscription may still purchase individual issues. The following payment options and fees are available.

Purchase an issue: 50.00 (USD)

You can purchase the access for all articles published in one issue. Access to articles will be provide for an unlimited time.

Access to issue allows you to read, download and print full text (PDF and HTML) of all articles, but does not allow to distribute, copy or reproduce articles materials until the end of the embargo period (3 years) since the publication of the article).

 

Article Purchase

Readers without a subscription may still purchase individual articles. The following payment options and fees are available.

Purchase an article: 5.00 (USD)

You can purchase the access for the article to read, download and print its fulltext (PDF, HTML). Access to article will be provide for an unlimited time.

Purchased access does not allow to distribute, copy or reproduce article's materials until the end of the embargo period (3 years) since the publication of the article).

 

Archiving

The journal uses the PKP Preservation Network (PKP PN) to digitally preserve all the published articles. The PKP PN is a part of LOCKSS (Lots of Copies Keep Stuff Safe) program offers decentralized and distributed preservation, seamless perpetual access, and preservation of the authentic original version of the content.

Also, the journal makes full-text archives on the Russian Science Electronic Library (http://elibrary.ru/) platform.

 

Publication Ethics Policy

The Ethics policy of "Russian Journal of Allergy" is based on recomendations from international commettees:

Reporting standarts

The Russian Journal of Allergy journal editorial team ask authors of reports of original research to present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.

Data Access and Retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines (based on ICMJE guidelines):

All authors whose names appear on the submission:

  1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work AND
  2. drafted the work or revised it critically for important intellectual content AND
  3. approved the version to be published AND
  4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.

Submissions by anyone other than one of the authors will not be considered.

Research Ethics and Patient Consent (Statement of Human and Animal Rights)

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

Hazards for Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Research involving human embryos, gametes, and stem cells

Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals)

The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent (See also Informed consent) was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Copies of approval and redacted consent documents may be requested by the Journal.

We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.

In deciding whether to publish papers describing modifications of the human germline, the Journal is guided by safety considerations, compliance with applicable regulations, as well as the status of the societal debate on the implications of such modifications for future generations. In case of concerns regarding a particular type of study the Journal may seek the advice from the Springer Nature Research Integrity Group.

The decision to publish a paper is the responsibility of the Editor-in-Chief of the Journal.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Conflicts of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Conflicts include the following:

  • Financial — funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work;
  • Affiliations — being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work;
  • Intellectual property — patents or trademarks owned by someone or their organization;
  • Personal — friends, family, relationships, and other close personal connections;
  • Ideology — beliefs or activism, for example, political or religious, relevant to the work;
  • Academic — competitors or someone whose work is critiqued.

For more information on conflicts of interest, see the guidance from the ICMJE and WAME.

Funding and Acknowledgement of Sources

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/  

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

Plagiarism

Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Only original works are acceptable for publication in "Russian Journal of Allergy". The journal does not allow any forms of plagiarism. Authors must not use the words, figures, or ideas of others without attribution. All sources must be cited at Russian Journal of Allergy take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. All the submitted articles are evaluated with plagiarism-checking software (Antiplagiat). Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to:

  • publishing an erratum or corrigendum (correction);
  • retracting the article;
  • taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies;
  • or taking appropriate legal action.

Also you can see ORI Avoiding Plagiarism, Self-plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing

Duplicate Submission and Redundant Publication

Russian Journal of Allergy consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.

Manuscripts submitted to Russian Journal of Allergy must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.

If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.

Russian Journal of Allergy will consider extended versions of articles published at conferences provided this is declared in the cover letter, the previous version is clearly cited and discussed, there is significant new content, and any necessary permissions are obtained.

Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.

Citation Manipulation

Authors whose submitted manuscripts are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, may incur sanctions.

Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.

Fundamental errors in published works, Corrections and Retractions

When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s). 

Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum (see more).

If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice. 

The journal use the CrossMark technology (by Crossref) to work with Corrections, Retractions and Editorial expressions of concern for Please, see the details on the CrossMark Policy for Pharmarus Print Media page.

Sanctions

If Russian Journal of Allergy becomes aware of breaches of our publication ethics policies, the following sanctions may be applied:

  • Rejection of the manuscript and any other manuscripts submitted by the author(s).
  • Not allowing submission for 1–3 years.
  • Prohibition from acting as an editor or reviewer.

Russian Journal of Allergy may apply additional sanctions for severe ethical violations.

 

Advertising Policies

Our advertising policy is consistent with the principles mentioned in the Recommendations on Publication Ethics Policies for Medical Journals which issued by the World Association of Medical Editors (WAME).

http://www.wame.org/recommendations-on-publication-ethics-policie

  1. Russian Journal of Allergy and it's Publisher (Pharmarus Print Media) generate revenue from advertising, which creates a potential conflict of interest. Editors’ decisions do not depend on the cost of advertising or producing reprints. Advertisers and sponsors have no influence over the editor’s decisions, regardless of the terms of advertising or other agreements.
  2. All advertisements are subject to the approval of the  Russian Journal of Allergy editorial team and Pharmarus Print Media's staff, which reserves the right to reject or cancel any advertisement at any time.
  3. The functions of Russian Journal of Allergy editors and Pharmarus Print Media's advertising managers are separate.
  4. In the Russian Journal of Allergy professional (physician-directed) publications and web site, the intentional placement of advertising adjacent to articles discussing the company or product that is the subject of the advertisement is prohibited. Advertising content must be distinguished from editorial and other materials so that the difference between them is obvious.
  5. Pharmarus Print Media will not publish “advertorial” content in Russian Journal of Allergy, and sponsored supplements must be clearly indicated as such. If a supplement did not undergo peer review or underwent a peer review-process different from the rest of the journal that should be explicitly stated.
  6. The Russian Journal of Allergy editorial team have the right to refuse any advertisement that, in its sole discretion, is incompatible with its mission or inconsistent with the values of members, the publication/web site or the organization as a whole, and to stop accepting any advertisement previously accepted. Advertisements are subject to review by the editors of the Russian Journal of Allergy and Pharmarus Print Media's stuff. In no case shall separate agreements with Pharmarus Print Media or its subsidiaries supersede this policy.
  7. Once an advertisement has been deployed online, it will be withdrawn from the journal site at any time if the Editor(s)-in-Chief or Pharmarus Print Media's staff request its removal.
  8. Advertising for the following categories is prohibited:
    • Alcohol
    • Tobacco
    • Weapons, firearms, ammunition
    • Fireworks
    • Gambling and lottery
    • Pornography or related themes
    • Political and religious advertisements
    • Advertisements that claim to have a “miracle” cure or method
    • Advertisements that make unsubstantiated health claims for the products advertised
    • Advertisements directed at children
  9. Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered. Exaggerated or extravagantly worded copy will not be allowed. Advertisements will not be accepted if they appear to be indecent or offensive in either text or artwork, or if they relate to content of a personal, racial, ethnic, sexual orientation, or religious nature.
  10. All advertisements are accepted and published in Russian Journal of Allergy on the warranty of the advertisement agency and advertiser that both are authorized to publish the entire contents and subject matter of the advertisement.
  11. In consideration of publication of an advertisement, the advertiser and the advertisement agency, jointly and severally, agree to indemnify and hold harmless Pharmarus Print Media, its officers, agents and employees against expenses (including legal fees) and losses resulting from the publication of the contents of the advertisement, including, without limitation, claims or suits for libel, violation of privacy, copyright infringement, or plagiarism.
  12. Any references to Russian Journal of Allergy and Pharmarus Print Media or its products or services in advertisements, promotional material, or merchandising by the advertiser or agency is subject to Pharmarus Print Media’s written approval for such use.
  13. All advertisements for drug-specific campaigns must comply with the relevant Russian legislation that regulates advertising. Advertisers should make available to Pharmarus Print Media the marketing authorization and summary of product characteristics when submitting their advertisement. In the case of drug advertisements, proprietary names of pharmaceutical products must be accompanied by the chemical, generic, or official name; the quantity of all active substances must be stated along with the recommended dosage. Each page of an advertisement for a prescription-only medicine should be clearly labeled as intended for health professionals.
  14. Advertisements for products not approved by the FDA or the Ministry of Health of Russian Federation that make any kind of health claims must carry the following disclaimer: “These statements have not been evaluated by the Food and Drug Administration and/or the Ministry of Health of Russian Federation. This product is not intended to diagnose, treat, cure or prevent any disease.”
  15. While Pharmarus Print Media welcomes and encourages information-rich advertising in Russian Journal of Allergy, advertisements, advertising icons and advertiser logos must be clearly distinguishable from editorial content and may require special labeling to distinguish them as such. All advertisements must clearly and prominently identify the advertiser by trademark or signature.
  16. Reprints should be published only in the form in which they were originally published in the journal (including subsequent corrections), so there should be no additions or changes in them.
  17. Pharmarus Print Media is not responsible for incidental or consequential damage for errors in displaying or printing an advertisement.
  18. Advertisements may not imply endorsement by the Russian Journal of Allergy or its publications/web site except as may be provided for under a separate agreement — in which case advertising must be pre-approved to ensure adherence to the letter and spirit of that separate agreement.
  19. The full rules for any market research or promotion associated with an advertisement must be displayed in the advertisement or available via a prominent link.
  20. The following online advertising formats are prohibited:
    • Pop-ups and floating advertisements.
    • Advertisements that collect personally identifiable information from visitors without their knowledge or permission.
    • Advertisements that extend across or down the page without the visitor having clicked or rolled-over the advertisement.
    • Advertisements that send visitors to another site without the visitor having clicked the advertisement.

Russian Journal of Allergy published advertising policies are not exhaustive and are subject to change at any time without notice.

We partner with third-party advertising companies to serve ads and/or collect certain information when you visit our website. These companies may use cookies or web beacons to collect non-personally identifiable information [not including your name, address, email address or telephone number] during your visit to this website to help show advertisements on other websites also likely to be of interest to you.

For contact with the Advertisement department of the Publisher, please, follow the link https://rusalljournal.ru/raj/about/contact.

 

Publication Fees

Publication in Russian Journal of Allergy is free of charge for all authors.

The Russian Journal of Allergy charge no obligatory publication fees from authors - including those of peer-review management, manuscript processing, journal production, online hosting and archiving.

There are some paid options for authors wich are not influence over the editorial decisions: publication in Open Access and Fast-Track editorial workflow. Details can be observed here.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies